newsfilter
← Latest News
GlobeNewswire·

Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

RMD
  • ResMed reported Q2 fiscal 2026 revenue of $1.42 billion, an 11% increase year-over-year and 9% on a constant currency basis.
  • Gross margin rose 320 basis points to 61.8%, while non-GAAP gross margin increased 310 basis points to 62.3%.
  • Income from operations grew 18% to $491.7 million, with non-GAAP income from operations rising 19% to $517.2 million.
  • Diluted earnings per share reached $2.68, compared to $2.34 in the prior year period; non-GAAP diluted EPS was $2.81.
  • Operating cash flow for the quarter totaled $340 million.
  • Revenue growth was driven by increased demand for sleep devices, masks, and accessories, with constant currency growth of 11% in the U.S., Canada, and Latin America, and 6% in Europe, Asia, and other markets.
  • Selling, general, and administrative expenses increased 12% on a constant currency basis, primarily due to VirtuOx acquisition costs, employee costs, and marketing investments.
  • The company recorded $6 million in restructuring-related charges following workforce planning activities.
  • ResMed announced FDA clearance for Smart Comfort, an AI-enabled digital medical device designed to personalize CPAP settings.
  • The board declared a quarterly cash dividend of $0.60 per share with a record date of February 12, 2026, and payment date of March 19, 2026.
  • Shareholders received $88 million in dividends, and the company repurchased 704,000 shares for $175 million during the quarter.
  • New research published in SLEEP indicated that each additional hour of PAP use reduced healthcare utilization by 4.1-6.2% over 12-24 months.
  • Six-month revenue for the period ended December 31, 2025, was $2.76 billion, representing a 10% increase from the prior year.